Literature DB >> 28826994

Effectiveness and cost-effectiveness of nationwide campaigns for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands.

Charles W Helsper1, Mart P Janssen2, Gerrit A van Essen3, Esther A Croes4, Clary van der Veen5, Ardine G de Wit6, Niek J de Wit7.   

Abstract

BACKGROUND: Hepatitis C virus infection (HCV) is a serious, but underdiagnosed disease that can generally be treated successfully. Therefore, a nationwide HCV awareness campaign was implemented in the Netherlands targeting people who inject drugs (PWID) in addiction care ('PWID intervention') and high-risk groups in the general population ('public intervention'). The objective of this study is to assess the effectiveness and cost-effectiveness of the interventions used in this campaign.
METHODS: For the 'PWID' intervention, all addiction care centres in the Netherlands provided proactive individual HCV consultation and testing. The 'public intervention' consisted of health education through mass media and instruction of health care professionals. A Markov chain model was used to estimate incremental cost-effectiveness ratios (ICER, cost per QALY gained). We included a 'DAA treatment' scenario to estimate the effect of these treatment strategies on cost-effectiveness.
RESULTS: The 'PWID intervention' identified 257 additional HCV-carriers. The ICER was €9056 (95% CI: €6043-€13,523) when compared to 'no intervention'. The 'public intervention' identified 38 additional HCV-carriers. The ICER was €18,421 (95% CI: €7376-€25,490,119) when compared to 'no intervention'. Probabilistic sensitivity analysis showed that the probability that the 'PWID intervention' was cost-effective was 100%. It also showed a probability of 34% that the 'public intervention' did not exceed the Dutch threshold for cost-effectiveness (€20,000). New treatment regimens are likely to improve cost-effectiveness of this strategy.
CONCLUSION: In a nationwide HCV awareness and case finding campaign, the intervention targeting PWID was effective and cost-effective. An intervention targeting risk groups in the general population showed only a modest effect and is therefore less likely to be cost-effective.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Campaign; Case finding; Cost-effectiveness; Hepatitis C; Primary prevention

Mesh:

Year:  2017        PMID: 28826994     DOI: 10.1016/j.drugpo.2017.07.022

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  5 in total

1.  Introducing hepatitis C virus healthcare pathways in addiction care in the Netherlands with a Breakthrough project: a mixed method study.

Authors:  Patricia A M Kracht; Elisabeth A de Gee; Agnes van der Poel; Marc A M T Verhagen; Andy I M Hoepelman; Esther A Croes; Joop E Arends
Journal:  Harm Reduct J       Date:  2019-07-15

2.  The Copenhagen test and treat hepatitis C in a mobile clinic study: a protocol for an intervention study to enhance the HCV cascade of care for people who inject drugs (T'N'T HepC).

Authors:  Jeffrey Victor Lazarus; Anne Øvrehus; Jonas Demant; Louise Krohn-Dehli; Nina Weis
Journal:  BMJ Open       Date:  2020-11-09       Impact factor: 2.692

Review 3.  Strategies for achieving viral hepatitis C micro-elimination in the Netherlands.

Authors:  P A M Kracht; J E Arends; K J van Erpecum; A Urbanus; J A Willemse; A I M Hoepelman; E A Croes
Journal:  Hepatol Med Policy       Date:  2018-09-29

4.  Disease burden of hepatitis C in the Austrian state of Tyrol - Epidemiological data and model analysis to achieve elimination by 2030.

Authors:  Benedikt Schaefer; André Viveiros; Ramona Al-Zoairy; Sarah Blach; Samantha Brandon; Homie Razavi; Livia Dorn; Armin Finkenstedt; Maria Effenberger; Ivo Graziadei; Mario Sarcletti; Herbert Tilg; Heinz Zoller
Journal:  PLoS One       Date:  2018-07-12       Impact factor: 3.240

5.  The cost-effectiveness of an HCV outreach intervention for at-risk populations in London, UK.

Authors:  Zoe Ward; Linda Campbell; Julian Surey; Steven Platts; Rachel Glass; Matthew Hickman; Alistair Story; Peter Vickerman
Journal:  J Antimicrob Chemother       Date:  2019-11-01       Impact factor: 5.790

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.